Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | RETAIN-2: risk enabled therapy after neoadjuvant chemo-IO in MIBC

Elizabeth Plimack • 15 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer Antibodies Checkpoint Inhibitors
RETAIN-1 RETAIN-2

The RETAIN-1 trial (NCT02710734) assessed a risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer. Elizabeth Plimack, MD, MS, Fox Chase Cancer Centre, Philadelphia, PA, discusses interim results from Phase II RETAIN-2 trial (NCT02710734) of neoadjuvant chemoimmunotherapy in muscle-invasive bladder cancer (MIBC). A promising bladder-preservation rate was reported and those undergoing cystectomy had a notable rate of complete response. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elizabeth Plimack

Updated results of axitinib and nivolumab in previously treated mRCC
0:32
Updated results of axitinib and nivolumab in previously treated mRCC
Elizabeth Plimack • 15 Feb 2025
CheckMate 274: additional survival outcomes of adjuvant nivolumab in MIBC
1:02
CheckMate 274: additional survival outcomes of adjuvant nivolumab in MIBC
Elizabeth Plimack • 15 Feb 2025
NIAGARA: impact of pCR on outcomes of durvalumab with NAC in MIBC
0:35
NIAGARA: impact of pCR on outcomes of durvalumab with NAC in MIBC
Elizabeth Plimack • 15 Feb 2025
DAD trial: combining sacituzumab govitecan and EV for the treatment of bladder cancer
0:52
DAD trial: combining sacituzumab govitecan and EV for the treatment of bladder cancer
Elizabeth Plimack • 22 Oct 2023

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals